Liposome encapsulated doxorubicin for the treatment of AIDS-associated Kaposi's sarcoma (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Liposome encapsulated doxorubicin for the treatment of AIDS-associated Kaposi's sarcoma (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A1139 1994. Unique Identifier : AIDSLINE ICDB/94602825
Harrison M; Coker R; Tomlinson D; Stewart S; Dept. of Oncology, St Mary's Hosp., London W2 1NY, UK

Abstract: Severe KS requiring chemotherapy affects 20-30% of patients with AIDS. Doxorubicin within a polyethylene glycol containing liposome (Doxil, LTI) has been used in a phase 2 study on 34 patients with severe KS. The liposome is 90 nm in diameter and is composed of 20% cholesterol, 20% polyethylene glycol, and 60% phosphatidyl choline. Polyethylene glycol within the lipid membrane decreases uptake by the reticuloendothelial system resulting in a half-life of 33-43 hours. A dose of 20 mg/m2 of doxorubicin was given 2-3 times weekly on an outpatient basis via peripheral venous access. A total number of 138 treatments were given, the maximum for any single patient was 20. A response rate of 76% was observed with 2 (6%) CR and 24 (70%) PR. Toxicity was mild, 3 patients (9%) developed WHO grade I alopecia and 6 patients (18%) WHO grade I nausea and vomiting. Antiemetics were not routinely given and not all these episodes of nausea were attributed to Doxil. Quality of life assessments showed that Doxil to be well tolerated with minimal interruption in the patients lifestyle.
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/*DRUG THERAPY Doxorubicin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS Drug Carriers Human Liposomes Metabolic Clearance Rate/PHYSIOLOGY Sarcoma, Kaposi's/BLOOD/*DRUG THERAPY Skin Neoplasms/BLOOD/*DRUG THERAPY ABSTRACTKWDacquiredimmunodeficiencysyndrome/blood/KWDdrugtherapydoxorubicin/KWDadministration&dosage/adverseeffects/pharmacokineticsdrugcarriershumanliposomesmetabolicclearancerate/physiologysarcoma,kaposi's/blood/KWDdrugtherapyskinneoplasms/blood/KWDdrugtherapyabstract
941230
M94C4332

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .